TPP2

Tripeptidyl-peptidase 2

0 patent compounds predicted against TPP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Germline variants in TPP2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TPP2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TPP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	PHASE4	COMPLETED
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome	PHASE4	COMPLETED
The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes	PHASE4	UNKNOWN
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Sitagliptin and Endothelial Dysfunction	PHASE3	UNKNOWN
The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy	PHASE3	COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease	PHASE1/PHASE2	RECRUITING
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency	PHASE2	COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus	PHASE2	COMPLETED
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.	PHASE2	COMPLETED
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis	PHASE1	COMPLETED
Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)	PHASE1	COMPLETED
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus	PHASE1	COMPLETED
Pappalysin 2 (PAPP-A2) Enzyme Replacement	PHASE1	COMPLETED
Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop	PHASE1	COMPLETED
Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis	nan	UNKNOWN
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients	nan	ACTIVE_NOT_RECRUITING
Genetic Analysis of Thyrotoxic Periodic Paralysis	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors	nan	UNKNOWN
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders	nan	RECRUITING
Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects	nan	UNKNOWN
DPP4 Activity, Microvascular Reactivity and Inflammation	nan	COMPLETED
Ovarian Reserve and Matrix Metalloproteinases	nan	COMPLETED
Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database	nan	UNKNOWN
Early Check: Expanded Screening in Newborns	nan	ENROLLING_BY_INVITATION
InsightRP2 Registry	nan	RECRUITING
Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients	nan	COMPLETED
Exploring Biomarkers in Hereditary Transthyretin Amyloidosis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TPP2 binder may also engage these)

Protein	Name	Similarity
Q64514	—	1.000	Q64514 →
Q64560	—	1.000	Q64560 →
A5PK39	—	1.000	A5PK39 →
F4JVN6	—	0.977	F4JVN6 →
Q6ESI7	—	0.976	Q6ESI7 →
A0FKG7	—	0.972	A0FKG7 →
Q5ZKY2	—	0.970	Q5ZKY2 →
P82922	—	0.969	P82922 →
Q5R8R4	—	0.968	Q5R8R4 →
Q9Y6W3	—	0.968	Q9Y6W3 →
Q5RAK7	—	0.967	Q5RAK7 →
Q641Y5	—	0.967	Q641Y5 →
Q9HD40	—	0.966	Q9HD40 →
Q9R1S8	—	0.965	Q9R1S8 →
Q4V7N2	—	0.965	Q4V7N2 →
Q5R6E0	—	0.964	Q5R6E0 →
ATG7	Ubiquitin-like modifier-activating enzyme ATG7	0.964	landscape →
Q5RGJ5	—	0.964	Q5RGJ5 →
Q5XGS8	—	0.964	Q5XGS8 →
Q8C878	—	0.964	Q8C878 →
Q5R4A0	—	0.964	Q5R4A0 →
DAP3	Small ribosomal subunit protein mS29	0.964	landscape →
B4G0F3	—	0.964	B4G0F3 →
O55236	—	0.963	O55236 →
UBA3	NEDD8-activating enzyme E1 catalytic subunit	0.963	landscape →
Q9SV20	—	0.963	Q9SV20 →
Q9ER88	—	0.963	Q9ER88 →
A4FUD3	—	0.963	A4FUD3 →
RNGTT	mRNA-capping enzyme	0.963	landscape →
Q6NYU2	—	0.963	Q6NYU2 →